
Oryzon to invest eur 20 million to develop new drugs
Catalan Economy
10 Sep 2009
Biotech company oryzon genomics has announced a four-year program to invest eur 20 million in the development of new drugs. oryzon ceo carlos buesa indicated that the company would use the resources to strengthen its research on biomarkers and antibody therapy.
oryzon recently opened its new 2,300-square-meter corporate headquarters in cornellà de llobregat (barcelona), with an investment of eur 2.5 million. the company expects revenue of eur 8 million for its current fiscal year.
source: expansión catalunya, 08/09/09
Related News and Success stories.
-
28 Jul 2025
Catalonia to launch Europe’s first 6G Low Earth Orbit satellite lab
-
21 Jul 2025
Barcelona's Exponential Day 2025: Vanessa Cann unveils the next AI revolution
-
18 Jul 2025
Catalonia moves up as a Strongly Innovative European Region and leads Spain
-
17 Jul 2025
Grifols invests €160 million in Barcelona and creates 400 jobs with a new plasma fractionation plant